Angle
Medtech company ANGLE has apopointed James Reuben, PhD, MBA, as a Scientific Advisor to the company with immediate effect.
Dr. Reuben is a Professor in the Department of Hematopathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center, Houston, Texas. He has conducted extensive research on circulating tumour cell (CTC) subsets, including those with epithelial and mesenchymal phenotypes and their clinical relevance to minimal residual disease in breast cancer.
The University of Texas MD Anderson Cancer Center is one of the world’s most respected centres devoted exclusively to cancer patient care, research, education and prevention. A different part of MD Anderson is already working with ANGLE as a key opinion leader in the field of colorectal cancer.
Dr. Reuben is a leader in translational medicine at MD Anderson and in particular in the area of CTCs and liquid biopsies, a key area of medical development in which he has been working for many years. Translational medicine is the field involved in taking new research and getting it applied in the treatment of patients.
ANGLE founder and chief executive Andrew Newland commented: “Jim Reuben has exceptional knowledge of circulating tumour cells. He was one of the leading investigators in the earliest studies on CTCs and has been very actively involved ever since. We are delighted that he has joined ANGLE’s scientific advisory board and believe his in-depth knowledge and understanding of CTCs and wide network of contacts in the field will be of great benefit to ANGLE as we drive towards the widespread adoption of the Parsortix system in cancer care.”